We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
We need "regulatory clearances both in the UK and internationally" then we'll be up and away. Its clear that ODX management want to line their ducks in a row before they provide numbers for the other tests. It seems strange that BATM has been valued differently though.
https://www.heraldscotland.com/business_hq/18582438.investors-crave-information-omega-reveals-full-year-results/?ref=twtrec
"Omega is projecting total revenues of £12.6m for the coming year, more than £8m of which will be generated by sales of food intolerance testing kits. The remainder is expected to be roughly divided between its CD4 diagnostic for HIV and Covid-19 antibody tests.
House broker finnCap said the scope for this forecast to be beaten is “very possible”, but depends on regulatory clearances both in the UK and internationally. Omega’s revenue guidance does not include its part in the UK Rapid Test Consortium (UK-RTC), which is expected to begin shipping kits in September, nor its three other Covid-19 development projects with Mologic."
Explain the discrepancy in valuations between BATM and ODX then RattyRy. FYI I've done well from BATM and hope to do well from ODX too.
https://www.investegate.co.uk/batm-advanced-comm/bvc/batm-expands-covid-19-diagnostic-tests/202007150700070092T/?fe=1&utm_source=FE%20Investegate%20Alerts&utm_medium=Email&utm_content=Announcement%20Alert%20Mail&utm_campaign=BATM%20Advanced%20Comm%20Alert
BATM have just announced the launch of three new diagnostic kits to significantly advance the diagnosis of COVID-19 and other respiratory illnesses. The tests are 1. COVID-19 serologic test 2. COVID-19 antigen test and 3. New molecular diagnostics test. The Group expects to commence sales and production of the kits at its Adaltis facility in Italy at the end of Q3/beginning of Q4 2020.
There's room for other companies in tackling covid-19 as there is huge demand so competition is not an issue IMO but I wanted to highlight the number of companies investing substantial funds in research, development and production in tacking covid-19. They must all be pretty confident that covid-19 will be with us for the foreseable future.
ODX are well placed to take advantage with UK government backing that will enable it to fast track its productions and start supplying before companies like BATM start manufacturing their products. Its also interesting to note that BATM have added £380m to their market cap since the covid-19 outbreak, they have a stronger core business than ODX and have sold a substantial amount of ventilators to a European customer recently but the discrepancy between the company valuations is huge. ODX are only valued at around £60m and BATM have added £380m to their market cap (currently £580m) since the start of the outbreak, once ODX have firm orders I think this gap will start to get filled very quickly.